Metronomic capecitabine as extended adjuvant chemotherapy for early triple-negative breast cancer (SYSUCC-001): updated 10-year outcomes and post-hoc exploratory biomarker analysis from a randomised, phase 3 trialJing Yuan, Yong-Yi Zhong, Xulin Wang et al.|The Lancet Oncology|2025Cited by 5